CLSN News Alert Celsion Corp (CLSN) 2.39 12/25/2014 07:00:31

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celsion Corp (CLSN) 2.39 $CLSN

Insider Trading Alert - GWRE, CLSN And ADI Traded By Insiders
at The Street - Tue Dec 23, 1:30PM CST
Stocks with insider trader activity include GWRE, CLSN and ADI
CLSN: 2.39 (+0.06), GWRE: 51.54 (+0.28), ADI: 56.71 (+0.05)

Celsion's Prospects For A Significant Upside Just Got A Lot Better
Clinically Sound Investor - at Seeking Alpha - Thu Nov 20, 11:12AM CST

CLSN: 2.39 (+0.06)

Celsion net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:18AM CST

CLSN: 2.39 (+0.06)

Celsion's (CLSN) CEO Michael Tardugno on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:54PM CST

CLSN: 2.39 (+0.06)

Celsion (CLSN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 11, 3:25PM CST

CLSN: 2.39 (+0.06)

Celsion misses by $0.03, revenue in-line
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:58AM CST

CLSN: 2.39 (+0.06)

Celsion Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Nov 11, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the third quarter ended September 30, 2014. The Company also provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, and two newly acquired technology platforms, TheraPlas(TM) and TheraSilence(TM), in immunotherapy and RNA delivery.
CLSN: 2.39 (+0.06)

Celsion Corporation Receives VHP Approval to Initiate OPTIMA Study in Europe
PR Newswire - Wed Nov 05, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Phase III OPTIMA Study was approved via Europe's centralized Voluntary Harmonization Procedure (VHP). The approval allows Celsion to conduct the OPTIMA Study, its Phase III trial of ThermoDox® in primary liver cancer, also known as hepatocellular carcinoma (HCC), in Europe. In addition to Italy, the OPTIMA Study will now include sites in Spain and Germany. The OPTIMA Study is the Company's global pivotal, double-blind, placebo-controlled trial, evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat patients with non-resectable HCC lesions. HCC is the largest unmet medical need remaining in oncology with annual incidence over 750,000 and non-resectable RFA candidates representing some 30% of the newly diagnosed patients. The OPTIMA Study is actively recruiting and enrolling patients at sites in the United States, Hong Kong, South Korea, Malaysia and Thailand. Additional clinical sites in Canada, Taiwan, and the Philippines are expected to begin recruitment before the end of the year with China FDA (CFDA) regulatory approval to follow in early 2015.
CLSN: 2.39 (+0.06)

Celsion reports November 11
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 10:50AM CST

CLSN: 2.39 (+0.06)

Celsion Corporation to Hold Third Quarter 2014 Financial Results Conference Call on Tuesday, November 11, 2014
PR Newswire - Tue Nov 04, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its third quarter 2014 financial results at 4:30 p.m. ET on Tuesday, November 11, 2014. To participate in the call, interested parties may dial 1-888-430-8709 (Toll-Free/North America) or 1-719-457-1512 (International/Toll) and ask for the Celsion Corporation Third Quarter 2014 Conference Call (Conference Code: 3981708) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
CLSN: 2.39 (+0.06)

Celsion Presents Preclinical Data for its TheraSilence(TM) Platform at the miRNA World Conference Workshop on miRNA Delivery
PR Newswire - Wed Oct 29, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced the presentation of data related to TheraSilence(TM), the Company's lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data was presented by Dr. Khursheed Anwer, Celsion's Executive Vice President and Chief Scientific Officer, during a panel presentation, and highlighted formulation characteristics of the TheraSilence delivery platform, preclinical proof-of concept data and data supportive of GEN-2 (formerly referred to as EGEN-002), Celsion's RNA interference (RNAi) therapeutic for the treatment of lung cancer. Celsion acquired the TheraSilence platform and GEN-2 through its acquisition of EGEN, Inc. in June 2014.
CLSN: 2.39 (+0.06)

Celsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors
PR Newswire - Tue Oct 07, 4:00PM CDT
Celsion Corporation (NASDAQ: CLSN) announced that the Board of Directors has appointed Michael H. Tardugno, the Company's President and CEO, to the additional position of Executive Chairman of the Board. Mr. Tardugno's appointment is consistent with the Board's previously established succession plan and follows the passing of Max E. Link, Ph.D. which was announced earlier today. At the direction of Mr. Tardugno, the Nominating Committee of the Board of Directors has begun the process to identify qualified candidates to fill the vacancy on the Company's Board.
CLSN: 2.39 (+0.06), ABT: 45.70 (-0.02), BMY: 59.15 (-0.01)

Celsion Announces The Unexpected Passing of Max E. Link, Ph.D., Chairman of the Board
PR Newswire - Tue Oct 07, 3:35PM CDT
Celsion Corporation (NASDAQ: CLSN) is saddened to announce the passing of Max E. Link, Ph.D., a Director and the Chairman of the Board of Directors of the Company. Dr. Link passed away unexpectedly at the age of 74.
CLSN: 2.39 (+0.06)

INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Celsion Corp. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Wed Sep 17, 1:18PM CDT
Levi & Korsinsky, LLP is investigating Celsion Corp. (NasdaqCM: CLSN) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
CLSN: 2.39 (+0.06)

Celsion Announces Highlights from Three Presentations Given at the International Liver Cancer Association 2014 Annual Conference
PR Newswire - Mon Sep 08, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced highlights from three presentations by three of the world's leading liver cancer experts and principal investigators for the Company's pivotal Phase III OPTIMA Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with standardized radiofrequency ablation (sRFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). The symposium, highly attended by physicians committed to HCC research, was conducted at the International Liver Cancer Association (ILCA) 7th Annual Conference from September 5 - 7, 2014 in Kyoto, Japan.
CLSN: 2.39 (+0.06)

Celsion Reports Consolidated Duke University and Celsion's DIGNITY Study Clinical Data on ThermoDox® in Recurrent Chest Wall Breast Cancer Published in the International Journal of Hyperthermia
PR Newswire - Thu Sep 04, 8:05AM CDT
September 4, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that data from two Phase I studies on ThermoDox® in recurrent chest wall breast cancer were published in the International Journal of Hyperthermia. The article, titled "Two phase 1 dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer," appears in the August 2014 issue (Volume 30, Number 5) and can be accessed here.
CLSN: 2.39 (+0.06)

Celsion Announces Enrollment of First Patient in Global Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
PR Newswire - Tue Sep 02, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient has been enrolled in its pivotal Phase III OPTIMA Study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) in patients with primary liver cancer, also known as hepatocellular carcinoma (HCC). ThermoDox® is Celsion's proprietary, heat-activated, liposomal encapsulation of doxorubicin.
CLSN: 2.39 (+0.06)

Celsion to Present at the Rodman & Renshaw 16th Annual Healthcare Conference
PR Newswire - Thu Aug 28, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that Michael H. Tardugno, Celsion's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16th Annual Healthcare Conference on Tuesday, September 9,, 2014 at 10:50 a.m. Eastern Time. The conference is being held at The New York Palace Hotel in New York City. A copy of the presentation will be available on Celsion's website at investor.celsion.com/events.cfm.
CLSN: 2.39 (+0.06)

Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.39 (+0.06), NWBO: 5.58 (+0.04), CVM: 0.62 (+0.03), CLDX: 17.08 (-0.18), INCY: 71.57 (+1.99), AZN: 70.44 (+0.26), MRK: 57.46 (+0.25), DNDN: 0.13 (-0.02), NLNK: 39.08 (+1.36), PPHM: 1.40 (+0.01), BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)

Celsion Corporation Reports Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 07, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014. The Company also provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, and two newly acquired technology platforms, TheraPlas(TM) and TheraSilence(TM), in immunotherapy and RNA delivery.
CLSN: 2.39 (+0.06)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 88

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 83

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading

Top 5 Most Recently Viewed Articles

Nukkleus Stock Skyrockets 16% After Major Decision

Updated Category News Views 330

Nukkleus Inc. Stock Soars in After-Hours Trading Nukkleus Inc. (NASDAQ: NUKK) is making headlines as its shares have surged during after-hours trading following important developments within the company. This noteworthy stock movement reflects both investor sentiment and strategic changes that the company is undergoing. After-Hours Rally Sparks Investor Interest In recent...

Continue Reading
Tambourine One Revolutionizes Hotel Booking Experiences

Updated Category News Views 135

Introducing Tambourine One: A New Era in Hotel Booking Tambourine, the renowned leader in hotel marketing technology, has launched an innovative product known as Tambourine One. This all-in-one solution merges their advanced website technology with a booking engine, aimed at boosting direct bookings for hotels and resorts. By enhancing the booking process, Tambourine One...

Continue Reading
Midwest Great Dane: A New Era for Trudell Trailer Sales

Updated Category News Views 217

Midwest Great Dane Reveals Brand Transformation Midwest Great Dane, previously known as Trudell Trailer Sales, is making waves in the transportation and trucking industry with its recent name change. This transformation stems from a strategic acquisition by Cox Automotive, aimed at enhancing their representation of the Great Dane brand in the Midwest. The organization's...

Continue Reading
SoftServe Launches New Partner Unit to Boost AI Solutions

Updated Category News Views 334

SoftServe Unveils New Partner Business Unit for Enhanced AI Services SoftServe has officially launched its first dedicated Partner Business Unit (BU), marking a significant step forward in its strategic partnership with Microsoft. This initiative is designed to leverage SoftServe's extensive experience in technology and digital services, ensuring that organizations can...

Continue Reading
Portugal's Agri-Food Push in Canada: A Taste for Growth

Updated Category News Views 52

Eyeing Fresh Opportunities in Canada Here's a hot one for you—Portugal's agri-food sector is making a notable splash over in Canada. Yeah, you heard it right. Amidst the hustle and bustle of the SIAL Canada, which isn't just any minor shindig, "Taste & Feel Portugal 2.0" aims to put Portugal's top-tier grub on the map. It's about more than nibbling on cheese; it's a...

Continue Reading